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Summary
 
A somatic process introduces mutations into antibody variable (V) region genes at a high rate in
many vertebrates, and is a major source of antibody diversity. The mechanism of this hypermu-
tation process remains enigmatic, although retrospective studies and transgenic experiments
have recently suggested a role for transcriptional regulatory elements. Here, we demonstrate
that mouse heavy (H) chain loci in which the natural V
 
H
 
 promoter has been replaced by a het-
erologous promoter undergo hypermutation. However, while the distribution of mutation in
such loci appears normal, the frequency of mutation does not. Conversely, moving the V
 
H
 
promoter 750 bp upstream of its normal location results in a commensurate change in the site
specificity of hypermutation in H chain loci, and the foreign DNA inserted into the V
 
H
 
 leader
intron to produce this promoter displacement is hypermutated in a manner indistinguishable
from natural Ig DNA. These data establish a direct mechanistic link between the IgH transcrip-
tion and hypermutation processes.
 
A
 
ntibody variable (V)
 
1
 
 gene hypermutation results in di-
versification of the antibody repertoire in a variety of
vertebrates (1). In mice and humans, this process is induced
during T cell–dependent immune responses, is intimately
associated with differentiation of memory B cells, and in
combination with antigen affinity based selection, results in
affinity maturation of serum antibodies (2). Past retrospec-
tive and descriptive studies in mice have shown that hyper-
mutation introduces mainly single, untemplated nucleotide
replacements at a rate estimated to be 10
 
2
 
3
 
/bp/cell division
(3–6), acts efficiently only in and immediately around fully
rearranged L chain V and V
 
H
 
 genes (i.e., in a “zone” from
 
z
 
300-bp 5
 
9
 
 to 1-kb 3
 
9
 
 of the V gene) (7–12), and is not
mechanistically linked to isotype switch or V(D)J recombi-
nation (13–16).
Current data lend the most support to models for the
mechanism of hypermutation that invoke a role for the
transcription apparatus. Mutations are rare in regions 5
 
9
 
 of
V gene promoters, suggesting a “boundary” (8, 11, 12, 17).
The distribution of mutations in and around a V gene ap-
pears to be influenced by the location of regions flanking
the 5
 
9
 
 side of the V coding sequence and not the V coding
sequence itself (10, 17). Since 5
 
9
 
 regions distal to V coding
sequence are clearly not required for hypermutation (18,
19), there may be an influence of the promoter region on
distribution. More recent studies using transgenic technol-
ogy have begun to shed light on the 
 
cis
 
-acting elements
necessary for hypermutation of V
 
k
 
 L chain genes. A role
for both the intronic and 3
 
9
 
 distal 
 
k
 
 transcriptional enhanc-
ers in influencing the rate of hypermutation of the Ig
 
k
 
 lo-
cus has been implicated (19), and the insertion of a V
 
k
 
 pro-
moter just 5
 
9
 
 of the C
 
k
 
 exon in an Ig
 
k
 
 transgene results in
somatic mutation of this normally unmutated region (20).
While it is not known whether transcription is required for
hypermutation or whether the influence of promoters and
enhancers on hypermutation is secondary to their role as
transcriptional regulators, these data nevertheless suggest
that common 
 
cis
 
-acting elements are involved in these pro-
cesses.
 
Materials and Methods
 
Transgenic Mice.
 
Transgenic mice were generated by standard
methods (21) using C57BL/6 
 
3
 
 C3H F1 mice and linearized plas-
mid constructs. Founder mice were backcrossed for two (“AA”
mice), three (“3A” mice), or four (“4A” mice) generations to the
A/J strain before use. All mice used in these experiments were
heterozygous for multicopy transgenic arrays. Mice were housed
under specific pathogen-free conditions and given autoclaved food
and water. All experimental procedures on mice were conducted
according to the National Institutes of Health guidelines.
 
Generation and Screening of Hybridomas.
 
All hybridomas were
generated from the spleens of 8–10-wk-old transgenic mice im-
munized with the same preparation of p-azophenylarsonate (Ars)-
KLH intraperitoneally using one of the following immunization
protocols: 10 d after a single injection of 100 
 
m
 
g Ars-KLH in
CFA (late primary), 3 d after secondary or tertiary boosting injec-
tions of 100 
 
m
 
g Ars-KLH in PBS at least 30 d after priming with
100 
 
m
 
g Ars-KLH in CFA, or 3 d after a regimen of priming with
 
1
 
Abbreviations used in this paper:
 
 Ars, arsonate; V, variable.
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100 
 
m
 
g Ars-KLH in CFA, a 7-d rest, and then four injections of
25–50 
 
m
 
g Ars-KLH in PBS spaced at 2-d intervals (fusion 16 d af-
ter initial priming, hyperimmunized primary). Supernatants from
the hybridomas were screened by ELISA for those expressing the
transgenic V
 
H
 
 gene using the antiidiotypic antibodies E4 and 107
as previously described (15). E4 recognizes all canonical anti-Ars
antibodies. 107 recognizes only canonical anti-Ars antibodies par-
tially encoded by the 36-65 V
 
H
 
 gene, due to the rare V
 
H
 
-D and
D-J
 
H
 
 junctional amino acids encoded by this gene (22, 23).
 
Reverse Transcriptase-PCR, Genomic PCR, and Nucleotide Se-
quencing.
 
Total RNA was prepared from hybridomas, reverse
transcriptase-PCR performed, and PCR products directly se-
quenced as previously described (24). The hybrid loci were ampli-
fied from hybridoma genomic DNA by PCR, and bulk PCR prod-
ucts were directly sequenced also as described previously (18, 25).
Since bulk PCR products were sequenced in all experiments, the
contribution of Taq polymerase error to mutations in the final se-
quences was considered to be insignificant.
 
Results
 
If Ig promoters contain 
 
cis
 
 information necessary for the
locus-specific action of hypermutation, replacement of the
natural promoter in an Ig locus with a heterologous, but
B cell–specific promoter should ablate hypermutation. More-
over, if the site specificity of mutation is regulated by the
promoter, changing the location of this element relative to
the VDJ coding sequence and downstream regulatory ele-
ments such as the intronic enhancer in an Ig locus should
cause a corresponding change in the location of the charac-
teristic “zone” of mutation. To test these predictions for
the IgH locus and its promoter we created transgenic mice
using two modified forms of a construct containing an anti-
Ars VDJ gene called 36-65 from A/J mice, a minimal V
 
H
 
promoter (145 bp containing only the cap/initiation site, a
TATA box, an octamer, a heptamer, and a purine rich re-
gion), and 1.5 kb of natural 3
 
9
 
 flanking sequence. In one
construct, the natural V
 
H
 
 promoter was replaced by the
heterologous, but B cell–specific minimal B29 (Ig-
 
b
 
) gene
promoter. In the second construct, the size of the intron
between the V
 
H
 
 leader exon and the main V
 
H
 
 exon was
enlarged 750 bp via insertion of a portion of a 
 
Drosophila
melanogaster
 
 myosin heavy chain gene intron. Since all of
the 
 
cis
 
-acting elements necessary for hypermutation of V
 
H
 
transgenes present at ectopic chromosomal sites have yet to
be defined (18, 26), we exploited a novel somatic recombi-
nation pathway (18, 25) to introduce our modified V
 
H
 
constructs into a natural context within the endogenous
(i.e., nontransgenic) H chain locus (Fig. 1).
We have previously shown (18, 25) that transgenes de-
rived from constructs containing the 36-65V
 
H
 
 gene and
various amounts of natural 5
 
9
 
 and 3
 
9
 
 flanking DNA (here-
after referred to as wild type) recombine with the endoge-
nous IgH locus at a low frequency in B cells, giving rise to
fully functional “hybrid” H chain genes that undergo nor-
mal hypermutation (Fig. 1). In such hybrid loci, the VDJ
and its 5
 
9
 
 flanking sequences are transgene derived, and re-
Figure 1. Transgene structure
and schematic representation of
the nonreciprocal recombina-
tion pathway leading to the gen-
eration of hybrid H chain loci.
CPM1 and CPM2 mice were
produced using a plasmid con-
taining the VH promoter, VH
leader exon, the unmutated, re-
arranged VDJ from the anti-
arsonate hybridoma 36-65, and
the unrearranged JH3-JH4 region
of the H chain locus. Inserted 25
bp 39 of the VH leader exon is a
750-bp piece of intron DNA
from between exons 12 and 13
of the D. melanogaster myosin
heavy chain gene. The BP2 mouse
line was generated using a plas-
mid similar to the one described
above except the 750-bp D.
melanogaster intron DNA is not
present and the minimal B29
promoter (38) was placed 43 bp
59 of the ATG in the VH leader
exon, replacing the natural VH
promoter. All transgenic mice
were generated as previously de-
scribed (24). Nonreciprocal re-
combination (gene conversion)
occurs as the result of homolo-
gous pairing between a region 39
of the coding VDJ of one transgene copy in the transgenic array and the analogous region in the IgH locus. The result is one copy of the transgenic array
being copied into the IgH locus at a natural position 59of the intronic enhancer. This recombination takes place at a low frequency, so most B cells from
the transgenic mice express a conventional H chain locus. DNA length scale bars are shown. 
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gions 3
 
9
 
 of the J
 
H
 
3–J
 
H
 
4 region are derived from the endog-
enous H chain locus. The kinetics and distribution of hy-
permutation are not altered in such hybrid loci, and the
generation of these loci is not mutagenic or mechanistically
linked to the hypermutation process (18, 24, 25).
Founder mice were crossed with A/J mice to introduce a
“canonical” V
 
k
 
 gene (V
 
k
 
10J
 
k
 
1), that normally is coexpressed
with canonical V
 
H
 
 genes, encoded by the same V
 
H
 
, D, and
J
 
H
 
 gene segments as the 36-65V
 
H
 
 gene, in a major fraction
of the B cells that respond to Ars immunization in the A/J
mouse strain (13). One line of mice obtained from the B29
promoter construct, termed BP2, and two lines of mice cre-
ated with the enlarged intron construct, termed CPM1 and
CPM2, were immunized with Ars-KLH and hybridomas
generated from late primary and secondary immune re-
sponses to sample the hypermutated B cell population. Hy-
bridomas coexpressing H chains encoded by a hybrid locus
and canonical endogenous 
 
k
 
 L chains were identified using
an antiidiotypic antibody specific for the 36-65 V region
(18, 24). The presence of hybrid loci in hybridoma ge-
nomic DNA was confirmed by Southern blot analysis (data
not shown).
Sequencing of the V
 
H
 
 genes present in B29 promoter-
driven hybrid loci expressed by late primary immune re-
sponse hybridomas via reverse transcriptase–PCR revealed
that these genes contained few or no somatic mutations.
Analysis of V
 
H
 
 genes in such hybrid loci expressed by sec-
ondary and tertiary hybridomas showed that they were
mutated, but also at levels lower than expected (Table 1).
However, the average frequency of mutation in expressed,
canonical V
 
k
 
 (V
 
k
 
10J
 
k
 
1) genes in these hybridomas was
comparable to that observed in canonical V
 
k
 
 genes ex-
pressed by control hybridomas (see legend to Table 1 and
Materials and Methods for details). The low frequency of
mutation observed in canonical V
 
k
 
 genes was anticipated
since previous studies on Ars-induced hybridomas derived
from A/J mice have shown that the frequency of canonical
V
 
k
 
 mutation is two to threefold lower than of canonical
V
 
H
 
 mutation (10, 15). Chi-squared comparison of the fre-
quency of mutations in the V genes expressed by hybrido-
mas derived from BP2 transgenic mice revealed the fre-
quency difference between endogenous canonical V
 
H
 
 genes
and B29 promoter-driven 36-65V
 
H
 
 genes present in hybrid
loci was highly significant (
 
P
 
 
 
,
 
10
 
2
 
4
 
). This difference in
mutation frequency is particularly apparent among primary
hybridomas. The significance of this difference is further
supported by the fact that hybridomas expressing hybrid or
endogenous H chain loci were often derived from the same
mouse, or from littermates immunized with the same anti-
gen preparation and from which fusions were performed at
the same time (see legend to Table 1). In contrast, the mu-
tation frequencies observed in the endogenous canonical
V
 
k
 
 genes expressed by these two groups of hybridomas
were not significantly different (
 
P
 
 
 
z
 
0.9). Thus, the hyper-
mutation process had operated normally in 
 
trans
 
 in the pre-
cursors to the hybridomas expressing B29 promoter-driven
hybrid loci.
Low levels of V
 
H
 
 mutation were also observed on aver-
 
Table 1.
 
Somatic Hypermutation in BP2, CPM1, and
CPM2 Hybridomas
 
Name of hybridomas
 
*
 
Isotype
Mutations
in V
 
H
 
Mutations
in V
 
k
 
BP2 hybridomas expressing hybrid H chain loci
Primary
4ABP2-8 G7 IgG2b 0 1
D10 IgG2b 0 0
E4 IgG2b 0 1
4ABP2-16 G6 IgG1 1 3
A5 IgG1 2 0
AABP2-2 E3 IgG2b 2 3
3APB2-7 H3 IgG2b 0 2
Secondary and tertiary
AABP2-28a E5 IgG1 1 1
3ABP2-59 A12 IgG1 7 1
D7 IgG2b 2 1
4ABP2-13 H7 IgG1 4 0
3ABP2-44 H8 IgG1 1 2
BP2 hybridomas expressing endogenous H chain loci
Primary
4ABP2-8 E7 IgM 3 0
AABP2-10 H7 IgG1 5 1
3ABP2-7 B1 IgG2b 4 4
4ABP2-23 F10 IgM 1 3
D2 IgG1 3 1
Secondary and tertiary
3ABP2-43 D3 IgG1 8 1
A12 IgG1 11 2
3ABP2-45 G2 IgG1 3 2
CPM hybridomas expressing hybrid H chain loci
Primary
3ACPM2-23 B2 IgG1 3 1
G6 IgG1 5 3
4ACPM1-2 D9 IgG1 2 4
G3 IgG1 0 4
C6 IgG3 0 1
4ACPM1-3 D5 IgG2b 3 2
F1 IgG3 12 2
 
*
 
The first four–five characters before the dash in each hybridoma name
indicate the name of the mouse from which that hybridoma was de-
rived. Among the BP2 hybridomas, the groups (4ABP2-8 D10, E4, E7,
G7); and (3ABP2-7 B1, H3) were derived from single mice. The
groups (3APB2-44 H8, 3ABP2-45 G2); (AABP2-2 E3, AABP2-10
H7) and (4ABP2-16 G6, A5, 4ABP2-23 D3, A12) were derived from
littermates immunized with the same dose and preparation of antigen
and sacrificed for fusion on the same day. 
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age in enlarged leader intron hybrid loci expressed by late
primary response hybridomas, and many such loci con-
tained no V
 
H
 
 mutations. As was the case for the hybrido-
mas containing B29 promoter-driven hybrid loci, the ca-
nonical V
 
k
 
 mutation frequency in hybridomas containing
enlarged leader intron hybrid loci appeared normal (data
from seven representative hybridomas are shown in Table 1).
As summarized in Fig. 2, the mutation frequencies in the
V
 
H
 
 genes in both types of hybrid loci are well below that
previously determined for wild-type 36-65V
 
H
 
 hybrid loci
at times late in the primary response.
The frequency of V
 
H
 
 gene mutation in hybrid loci is not
directly reflective of their intrinsic rate of mutation, as
many mutations in coding region can be selected in vivo.
Fig. 3 shows the sequence of the expressed V
 
H genes in the
B29 promoter-driven and enlarged leader intron hybrid
loci that contain at least one somatic mutation. Of the eight
VH genes in B29 promoter-driven hybrid loci, six contain
somatic mutations at positions 58 and 59 in CDR2 that are
recurrently observed among canonical VH genes. Two such
mutations have been shown to result in increased affinity
for Ars (27). In three such VH genes, these recurrent muta-
tions are the only mutations observed, and in one VH gene,
a recurrent mutation is one of only two mutations. Of these
four VH genes (those expressed by hybridomas 4ABP2-16G6,
AABP2-28aE5, 3ABP2-59D7, and 3ABP2-44H8), three are
expressed by hybridomas isolated from secondary or ter-
tiary responses. In wild-type 36-65VH genes in hybrid loci
and endogenous canonical VH genes, particularly those ex-
pressed by secondary and tertiary hybridomas, such muta-
tions are usually accompanied by many other “selectively
neutral” (e.g., silent) mutations (18, 28). Of the nine mu-
tated enlarged leader intron hybrid loci, five contain recur-
rent mutations. These data indicate that the frequency of
VH coding region mutation is an overestimate of the re-
duced intrinsic mutation rate in this region in both types of
modified hybrid loci, particularly those driven by the B29
promoter.
Figure 2. The total number of hybridomas expressing BP2 (B29 pro-
moter-driven) and CPM (enlarged leader intron) hybrid loci with a given
number of VH somatic mutations. Values for wild-type 36-65VH hybrid
loci were obtained from previously published data (18). All hybridomas
from CPM transgenic mice and wild-type 36-65VH transgenic mice were
generated using the hyperimmunized primary protocol and 8–10-wk-old
mice. For BP2 mice, primary, secondary, and tertiary immunization pro-
tocols were used (see Materials and Methods). Those hybrid locus ex-
pressing hybridomas from the B29 line that had the largest number of
mutations (.2) were from secondary and tertiary immunizations.
Figure 3. Nucleotide se-
quences of VH genes in hybrid
loci expressed by hybridomas
from BP2 (B29 promoter) trans-
genic mice (above solid line) and
CPM (enlarged leader intron)
transgenic mice (below solid line).
Only those sequences contain-
ing at least one mutation are
shown. The reference sequence
is that of the unmutated 36-
65VH gene. Hybridoma names
are listed to the left of each se-
quence. Dashed lines indicate se-
quence identity. Mutations are
shown explicitly. Only those
codons in which mutations
were observed, as well as junc-
tional codons, are shown. Re-
currently observed nucleotide
changes at codons 58 and 59 are
indicated in bold. The rare junc-
tional codons of the 36-65VH
transgene are underlined. Co-
dons are numbered sequentially
from the mature amino terminus, and the location of complementarity determining regions (CDR) are shown. At codon 58, the recurrent mutation
(ACT®ATT) results in a change from threonine to isoleucine, demonstrated to increase affinity for Ars two- to threefold (27). A variety of amino acid
substitutions have been recurrently observed at codon 59. A change from lysine to threonine (AAG®ACG), observed in two enlarged leader intron hy-
brid loci, increases affinity for Ars two- to fourfold (27). The lysine to asparagine mutation (AGG®AGC) observed at this position in 3 BP2 hybridomas
and 1 CPM hybridoma is recurrently observed, but its effect on Ars affinity has not been tested.243 Tumas-Brundage and Manser
Two explanations were considered for these observa-
tions: (a) the intrinsic rate of hypermutation throughout
the modified hybrid loci was reduced; and (b) the site spec-
ificity of hypermutation was altered such that the VH gene
no longer was present in the region of “peak” mutational
activity. To distinguish between these possibilities, hybrid
loci were cloned from hybridoma DNA and regions flank-
ing the 59 and 39 sides of the VH gene were sequenced.
Analysis of five B29 promoter-driven hybrid loci chosen to
represent the entire range of VH mutation frequency (i.e.,
0–7 VH mutations, hybridomas AABP2-2E3, 3ABP2-59A12,
and 4ABP2-13H7, -16A5, and -8D10) revealed that the
distribution of mutation was similar to wild-type 36-65VH
hybrid and endogenous canonical VH loci. However, mu-
tation frequencies in both 59 and 39 flanking regions were
low. In the 300 bp of DNA flanking the 59 side of VDJ,
only one mutation was observed in the 1.5 kb sequenced.
In the 1.5 kb of DNA flanking the 39 side of VDJ, only 23
mutations were observed in the 7 kb sequenced. However,
15 of these mutations were observed in the first 300 bp 39
of the VDJ. In previous analyses of the distribution of mu-
tation around endogenous canonical VH genes and 36-65VH
genes present in wild-type hybrid loci, 12–14% of the total
mutations were found 59 of the VDJ and 86–88% were
found 39 of VDJ (17, 18). Moreover, the majority of 39
mutations were observed within the first 300 bp 39 of VDJ
(see below). The chemical nature of mutations observed in
B29 promoter-driven hybrid loci was also characteristic of
bona fide hypermutation (29–32, and see below). Thus, the
effect of replacing the natural VH promoter with the B29
promoter appears to only be a reduction in the rate of hy-
permutation.
Sequencing of DNA flanking the 59 side of the VH gene
in seven enlarged leader intron hybrid loci revealed high
frequencies of mutation in both the Drosophila intron and
natural Ig intron regions (Fig. 4). However, few mutations
were observed in the region flanking the 39 side of VH in
these hybrid loci, a region that, as discussed above, displays
a high frequency of mutation in wild-type 36-65VH hybrid
and endogenous canonical VH loci (Fig. 5). These data in-
dicate that the distribution, but not the rate, of mutation
was altered due to the lengthening of the leader intron.
In wild-type 36-65VH hybrid and endogenous canonical
VH loci, the distribution of mutation encompasses z1 kb
with mutation frequency increasing abruptly near the leader
exon, peaking once in the main VH exon, and then gradu-
ally declining in 39 flanking DNA (Fig. 5). In the enlarged
leader intron hybrid loci, this distribution begins abruptly at
a similar location, but is larger and bimodel with the 39
peak encompassing the main VH exon (Fig. 4). We believe
that the shape of this distribution is not reflective of a
change in the intrinsic site specificity of hypermutation for
the following reasons. First, a major fraction of mutations
in the VH gene in these hybrid loci caused amino acid re-
placements in either CDR1 or CDR2, and could have
been positively selected by antigen (Fig. 3, and replacement
Figure 4. Mutation fre-
quency distribution in the en-
larged leader intron hybrid loci.
Seven hybridomas from three
different mice (two of the CPM1
line and one of the CPM2 line)
representing the entire range of
VH mutation observed (see Fig. 2
and Table 2) were analyzed. The
mutation frequency was deter-
mined as follows: number of mu-
tations in a 50-bp interval divided
by 350 (the total number of bases
in the interval sequenced from
all the hybridomas) 3 100. The
first 50-bp interval began 8 bp
59 of the purine rich motif in the
VH promoter. The solid lines un-
der the D. melanogaster intron in-
dicate those intervals that were
deleted from the hybrid loci in
hybridomas 4ACPM1-3F1 and
3ACPM2-23B2. A total of 350
bp were deleted from the
4ACPM1-3F1 hybrid locus; in
addition, this hybridoma also had
the most mutations in its V(D)J
coding sequence, 12, of any en-
larged leader intron hybridoma
analyzed. *, 39 flanking interval
in which two mutations were observed in the 4ACPM1-3F1 hybrid locus. A total of 470 bp were deleted from the 3ACPM2-23B2 hybrid locus. These
large deletions were scored as one mutation per interval deleted. The mutation frequency in the VDJ was calculated using either those mutations that do
not encode amino acid substitutions (silent mutations 2 stippled bars) or those mutations that encode amino acid changes (replacement mutations 2 diag-
onal striped bars).244 The IgH Promoter Regulates Hypermutation
mutation frequency in the VDJ is indicated by striped bars
in Fig. 4). Second, two such hybrid loci, those expressed
by hybridomas 4ACPM1-3F1 and 3ACPM2-23B2, con-
tain major deletions in the Drosophila intron DNA (Fig. 4).
We speculate that these deletions took place early during
the hypermutation process in vivo, subsequently allowing a
higher frequency of mutation to take place in the VH gene,
thus resulting in a higher probability of introduction of af-
finity enhancing mutations. Indeed, both of the enlarged
leader intron hybrid loci with intron deletions also contain
mutations in VH CDR2 known to be positively selected,
and one contains a total of 12 VH mutations, seven more
than any other enlarged leader intron hybrid locus exam-
ined. In total, these data argue that the transcriptional pro-
moter region dictates the site specificity of hypermutation
in the H chain locus.
Previous data obtained from the analysis of Igk trans-
genes in which major portions of the Vk exon were re-
placed by heterologous DNA showed that this DNA was
hypermutated (33). In agreement with these findings, our
results demonstrate that the Drosophila intron DNA is as
mutable as Ig DNA. An analysis of the types of mutations
in this DNA revealed that their chemical nature is similar to
that previously shown to be characteristic of somatic mu-
tation in Ig V region DNA and flanking sequence (29–32).
Of the 67 mutations scored, 65 were nucleotide substitu-
tions and 2 were single base insertions (Table 2). There
were also the two large (350- and 470-bp) deletions men-
tioned above. 48% of the mutations were transitions and
58% of the changes were from germline A residues. 34% of
the mutations occurred at either GC or TA dinucleotides
and 22% occurred in the trinucleotides AGC or TAC (or
their inverse repeats) previously identified as B cell somatic
hypermutation “hotspots” (30, 32). 17% of the mutations
occurred in the “RGYW” hotspot motif identified by
Rogozen and Kolchanov (29). Finally, a pairwise compari-
son of the frequency of mutations that, had they occurred
on different strands, would give rise to the same change
observed on one strand (e.g., A to G versus T to C) indi-
cated that the mutation took place with a strand bias of the
same polarity as that previously indicated from the analysis
of canonical endogenous VH genes (28).
Discussion
The experiments reported here provide a direct test of pre-
viously formulated hypotheses based on retrospective stud-
ies (8, 11, 17) proposing that the transcriptional promoter
plays a mechanistic role in the hypermutation process. The
data obtained demonstrate that the H chain promoter is the
Figure 5. Mutation fre-
quency distribution in enlarged
leader intron hybrid loci, wild
type 36-65VH hybrid loci, and
canonical endogenous IgH loci
from normal A/J mice. Hybrido-
mas expressing all enlarged leader
intron and wild-type 36-65VH
hybrid loci, and most endoge-
nous IgH loci were isolated us-
ing the hyperimmunized primary
protocol described in Materials
and Methods. Mutation fre-
quency was determined as de-
scribed in Fig. 4. Seven enlarged
leader intron hybrid loci were
analyzed. The data obtained
from intervals in the D. melano-
gaster intron from these hybrid
loci (Fig. 4) are not shown. Se-
quences of the four wild-type
36-65VH hybrid loci used to
generate this graph have been
previously described (18). The
eighteen normal A/J VH locus
sequences used were also previ-
ously described (17). For these
endogenous A/J loci, data was
not available for the first 59 inter-
val in the VDJ, and in the first
interval flanking the 39 side of
VDJ. *, 39 flanking interval con-
taining the two mutations from
the hybridoma 4ACPM1-3F1,
which had a 350-bp intron dele-
tion and the most VH mutations
(12) of any hybrid locus express-
ing hybridoma analyzed.245 Tumas-Brundage and Manser
Table 2. Location and Type of Somatic Mutations in Enlarged Leader Intron Hybrid Loci
Nucleotide
3ACPM2-23 4ACPM1-2 4ACPM1-3
B2 G6 D9 G3 C6 D5 F1
Vector
1
39 of Promoter
113 GTC®GGC
116 CTC®CAC
Leader intron
186 TAA®TCA
202 GGT®GCT
209 ATT®AAT
Dros. intron
247 TAG®TTG
249 CA®CCA
263 TGT®TCT
276 start D TGT®TAT
306 D CAT®CGT
324 D TAC®TCC
367 D
369 D CAC®CTC
375 D AAC®AGC AAC®AGC
391 D GTA®GAA
400 D ATG®AGG
414 D GAA®GCA
417 D TAT®TGT
427 D AAG®AGG
428 D AGT®AAT
431 D TAT®TTT
436 D CTT®CAT
441 D AGT®ACT
466 D CA®CCA
472 D AGC®AAC
479 D GAT®GGT
489 D AAA®ACA
509 D AAT®ATT
519 D start D
520 D TAA®TGA D
531 D TAA®TTA D
565 D GAT®GGT D
576 D AGT®AAT D
579 D AAT®ACT D
583 D TAC®TGC D
592 D TAT®TTT D
595 D GTA®GCA D
613 D TAT®TCT D
634 D TAC®TTC D
638 D TAA®TGA D
646 D TAC®TCC D
continued246 The IgH Promoter Regulates Hypermutation
Table 2. (continued)
Nucleotide
3ACPM2-23 4ACPM1-2 4ACPM1-3
B2 G6 D9 G3 C6 D5 F1
701 D TAT®TTT D
703 D TAG®TGG D
705 D GCA®GTA D
706 end D D
712 AGC®AAC D
715 AAT®AGT D
721 AGC®ATC D
726 TTC®TGC D
734 TTA®TAA D
735 TAT®TTT D
751 TAA®TGA D
756 AAG®AGG D
763 TTA®TAA D
773 GCC®GTC D
776 AAG®AGG D
794 TTT®TCT D
826 CGT®CTT D
845 CGT®CAT D
855 AAT®ATT D
857 TTT®TCT D
860 TAT®TTT TAT®TGT D
868 AAG®AGG D
869 end D
905 TAT®TGT TAT®TGT
926 GGT®GAT
951 and 952 ACC®ATT
954 CCT®CAT
956 TAA®TCA
968 AAT®ATT
Leader intron
977 AAG®AGG AAG®AGG
983 AAT®ACT
1006 TCC®TAC
FW 1
1068 AGC®ACC
1079 GGC®GAC
1110 GCT®GTT
1114 CTG®CAG
1119 TAT®TTT
CDR 1
1132 GCT®GTT
1139 TAT®TTT TAT®TGT
1141 TAA®TCA TAA®TGA
FW2
1152 AAA®AGA
1183 TTG®TAG
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cis-acting element that establishes the 59 boundary to hy-
permutation, and that hypermutation acts preferentially in a
1–1.5-kb region just 39 of this element irrespective of the
location of 39 flanking regulatory elements (such as the in-
tronic enhancer). Taken together with retrospective analy-
ses of the distribution of mutations in Igk and l loci (9, 10,
12, 17), recent results suggesting an important role for the
Vk promoter in influencing location of somatic mutations in
Igk transgenes (20), and the compatibility of the b-globin
promoter with hypermutation of Igk transgenes (19), our
data suggest that promoters perform a generic mutation di-
recting function in all loci subjected to hypermutation.
Since the heterologous B29 promoter is compatible with H
chain locus hypermutation, albeit at what appears to be a
reduced rate, the trans-acting factor(s) involved in regulat-
ing site specificity must interact with both VH and B29 pro-
moters. One likely candidate for such a factor is RNA
polymerase. Given this idea, the polarity of hypermutation
relative to the promoter is explained by the directionality
of transcription, and the rate of transcription is related to
the rate of hypermutation.
The conclusion that the B29 promoter supports a re-
duced rate of hypermutation appears, at face value, discor-
dant with the previous results of Betz et al. (19) who found
that replacing the natural Vk promoter with the human
b-globin promoter in an Igk transgene resulted in high lev-
els of Vk mutation. However, in their studies hypermuta-
tion was only evaluated in Peyer’s patch germinal center
B cells, a population known to undergo chronic antigen stim-
ulation and prolonged hypermutation. In this approach, the
frequency of transgene mutation cannot be compared to
endogenous internal control V genes. Moreover, careful ex-
amination of the data presented by Betz et al. (19) suggests
that the frequency of mutation observed in b-globin pro-
moter driven k transgenes is somewhat lower than in k trans-
genes in which transcription is driven by the natural pro-
moter.
If the rate of hypermutation is related to rate of tran-
scription, promoters with different activities should result
in different mutation rates. In this regard, the B29 pro-
moter has an approximately fivefold lower activity in in
vitro transfection experiments than the VH promoter/IgH
Table 2. (continued)
Nucleotide
3ACPM2-23 4ACPM1-2 4ACPM1-3
B2 G6 D9 G3 C6 D5 F1
CDR2
1190 TAT®TTT
1203 AAT®AGT
1204 ATG®AAG
1210 ATA®ACA
1212 ACT®ATT ACT®ATT ACT®ATT
1215 AAG®ACG
1216 AGT®ACT
FW3
1246 CAC®CTC
1255 TAG®TCG
CDR3
1357 ACT®ATT
1368 TAC®TCC
JH2-JH3
Intron
1479 TAT®TTT
1595 TTA®TCA
1597 ATA®ACA
1694
The left hand column lists the nucleotide positions observed to be somatically mutated in the enlarged leader intron hybrid loci. Nucleotide 1 is 148
nucleotides 59 of the initiation codon in the VH leader exon. The sequenced region ends 199 bases 39 of the VDJ. Various subregions of the hybrid
loci are labeled at the beginning of each subregion. The mutations observed in each of the seven hybrid loci are shown below the hybridoma names.
In each case the germline nucleotide triplet (or doublet in the case of the insertion mutations) is shown, as is the mutant nucleotide triplet, with the
mutant base underlined. The beginning and end of the large continuous deletions present in two of the hybrid loci are indicated by “start D” and
“end D” with all intervening nucleotide positions listed also indicated by “D”.248 The IgH Promoter Regulates Hypermutation
intron enhancer combinations (Wall, R., personal commu-
nication). However, it appears that the activity of the B29
promoter in hybrid loci and of the VH promoter in canoni-
cal endogenous loci is not greatly different in hybridoma
cells lines; Northern analysis of RNA from hybridomas de-
rived from BP2 mice revealed similar steady state levels of
H chain mRNA expressed from both types of loci (data
not shown). Nevertheless, the activity of the B29 promoter
in association with the H chain enhancers has not been as-
sessed in hypermutating B cells, and could differ from the
activity of VH promoters. Since quantitative analysis of gene
transcription rates in antigen specific germinal center B cells
is not yet technically feasible, further studies will be required
to resolve these issues.
Interestingly, B cell clones expressing B29 promoter-
driven hybrid loci appear to gain only limited access to the
memory B cell compartment. Only 10% of the BP2 hybri-
domas expressing a canonical VH and Vk isolated from sec-
ondary and tertiary fusions expressed a hybrid locus. In
contrast, nearly 50% of such BP2 hybridomas from primary
fusions expressed hybrid loci. Since affinity or specificity
enhancing mutations appear to be prerequisites for clonal
selection into memory (24, 34, 35), an attractive explana-
tion for this observation is that a lower rate of mutation
supported by the B29 promoter results in a lower probabil-
ity of sustaining these necessary mutations. It remains to be
determined whether the mutation rates supported by dif-
ferent VH and VL promoters differ substantially. If so, the
structure of this portion of a V gene may be as important as
the V(D)J coding region in determining whether a given
clonotype contributes to the memory B cell compartment.
The influence of the promoter on hypermutation rate
could result from indirect effects such as changes in DNA
accessibility or topology mediated by transcription. How-
ever, more direct effects of promoter function on hyper-
mutation rate (see below) could also be considered. How
this element might regulate the location of the characteris-
tic zone of hypermutation is less apparent. However, since
in our experiments a minimal VH promoter was used in the
enlarged leader intron transgene constructs, and replace-
ment of this promoter with the minimal B29 promoter in
the wild-type construct did not appear to alter the distribu-
tion of somatic mutation, this “mutation directing” activity
of the promoter must overlap substantially, if not com-
pletely, with its activity in directing transcription.
Two models for the hypermutation process have been
previously proposed that are particularly relevant in light of
these conclusions. Peters and Storb (20) have suggested that
a tissue-specific trans-acting mutator factor binds to RNA
polymerase during transcription initiation in Ig loci, and
that this factor-polymerase complex has a limited half-life
during elongation, restricting the intact complex from tran-
scribing DNA further than z1.5 kb from the promoter. In
this model, an increased frequency of “pausing” of the
polymerase induced by the mutator factor is thought to re-
sult in recruitment of enzymes involved in transcription-
coupled DNA repair that subsequently act in an error
prone fashion. Given the data presented here and by Betz
et al. (19) demonstrating that heterologous promoters are
compatible with hypermutation, an Ig locus–specific cis-
acting factor(s) other than the promoter would seem to be
necessary for “loading” of the factor into the transcription
initiation complex. Moreover, this model relies on the
rather ad hoc assumption that the action of transcription
coupled DNA repair, which normally repairs DNA damage
efficiently in regions in which RNA polymerase has paused
(36), is reversed, resulting in a substantially higher mutation
rate in these regions.
Steele and Pollard (37) have suggested that an RNA in-
termediate is involved in hypermutation. In their model,
error prone reverse transcription of this RNA intermediate,
followed by recombination of the mutant cDNA into the
template VDJ gene, results in mutational alteration of the
VDJ and flanking sequence. This model is consistent with
the nature of the promoter influencing the rate of hyper-
mutation, since this rate should be directly related to the
amount of RNA intermediate produced, which, in turn,
should be related to the rate of transcription. However, this
model attempts to account for the restricted distribution of
mutation by invoking a reverse transcription primer site(s)
between the V and C exons, thus resulting in mutant cDNAs
being produced only from this primer site to the mRNA
cap site. Our data are incompatible with this latter proposi-
tion, since moving the promoter 750 bp further upstream
of the V-C intron dramatically reduces mutation frequency
in this intron (Fig. 4).
Finally, neither of these models adequately accounts for the
lower frequency of mutation observed in transcribed regions
immediately 39 of the promoter (Fig. 5), which our data
suggest is a characteristic feature of the mutation mecha-
nism that is not influenced by the location of the promoter
or the type of DNA subjected to mutation (Fig. 4). Further
evaluation of these models will require experimental evalu-
ation of whether components of the Ig transcriptional ap-
paratus differ in B cells that have and have not activated the
hypermutation process, and whether hypermutating B cells
contain mutant Ig cDNA intermediates. Such studies will
undoubtedly provide new insight into the nature of the
trans-acting factors involved in the hypermutation process.
We would like to thank Dr. Mary Beth Davis for the D. melanogaster intron clone, Dr. Randy Wall for the
B29 promoter clone, Dr. Latham Claflin for suggesting the enlarged intron experiment, Judith Morgan for
construction of transgenic founders, William Monsell for technical assistance, and all other members of the
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